证券代码：603334 证券简称：丰倍生物 公告编号：2025-005 苏州丰倍生物科技股份有限公司 关于使用闲置自有资金进行现金管理的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 基本情况 | 投资金额 | 万元（含本数，下同） 10,000 | | --- | --- | | 投资种类 | 安全性高、流动性好、风险较低的理财产品 | | 资金来源 | 自有资金 | 已履行的审议程序 苏州丰倍生物科技股份有限公司（以下简称"公司"）于 2025 年 12 月 9 日召 开第二届董事会第七次会议，审议通过了《关于使用闲置自有资金进行现金管理 的议案》，该事项在董事会审批权限范围内，无需提交公司股东会审议。 特别风险提示 本着维护股东利益的原则，公司将严格控制风险，对现金管理产品投资严格 把关，谨慎决策。尽管公司购买的是安全性高、低风险、流动性好的理财产品或 存款类产品，但金融市场受宏观经济的影响较大。公司将根据经济形势以及金融 市场的变化合理地进行投资，但不排除该项投资受到市场波动的影响，敬请投资 者注 ...

苏州丰倍生物科技股份有限公司 关于使用募集资金置换预先投入募投项目及已支付发 行费用的自筹资金的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 苏州丰倍生物科技股份有限公司（以下简称"公司"）使用募集资金置换公 司预先投入募集资金投资项目的自筹资金人民币 319,496,043.10 元以及公司已支 付的各项发行费用的自筹资金人民币 4,614,791.15 元（不含增值税），合计使用 募集资金置换预先投入的自筹资金金额为人民币 324,110,834.25 元，符合募集资 金到账后 6 个月内进行置换的规定。现将有关情况公告如下： 证券代码：603334 证券简称：丰倍生物 公告编号：2025-003 一、募集资金基本情况 经中国证券监督管理委员会《关于同意苏州丰倍生物科技股份有限公司首次 公开发行股票注册的批复》（证监许可〔2025〕1958 号）核准，并经上海证券交 易所同意，公司向社会公众首次公开发行人民币普通股（A 股）3,590.00 万股， 并于 2025 年 11 月 5 日在上海证券 ...

二、董事会会议审议情况 （一）审议通过《关于变更公司注册资本、公司类型及修订<公司章程>并 办理工商变更登记的议案》 证券代码：603334 证券简称：丰倍生物 公告编号：2025-001 苏州丰倍生物科技股份有限公司 第二届董事会第七次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、董事会会议召开情况 苏州丰倍生物科技股份有限公司（以下简称"公司"）第二届董事会第七次 会议于 2025 年 12 月 9 日以现场结合通讯方式召开，会议通知于 2025 年 12 月 2 日以电子邮件形式等通讯方式通知各位董事。会议由公司董事长平原先生召集和 主持，会议应出席董事 9 名，实际出席董事 9 名，公司高级管理人员列席本次会 议。本次会议的召集、召开及表决程序符合《公司法》等法律法规、规范性文件 以及《公司章程》的规定。 鉴于公司首次公开发行人民币普通股（A 股）股票已完成，募集资金均已到 账，公司注册资本和公司类型发生变动，根据《公司法》等相关法律法规规定， 公司董事会同意变更公司注册资本以及公司类型，并对《 ...

Core Viewpoint - Suzhou Fengbei Biotechnology announced plans to engage in foreign exchange derivatives trading, including forward foreign exchange settlements and foreign exchange options, to mitigate risks associated with fluctuations in the foreign exchange market [1] Group 1: Business Strategy - The company and its subsidiaries intend to utilize up to $50 million (or equivalent currency) of idle funds for these transactions [1] - The trading period will not exceed 12 months, and the transaction amounts can be reused [1] Group 2: Risk Management - The company has established corresponding risk control measures, asserting that the business operations are necessary and feasible [1] - The maximum trading margin and premium will not exceed $2.5 million [1]

Company Overview - The company in focus is Fengbei Biological (603334), which specializes in the comprehensive utilization of waste resources, particularly known for its "waste oil refining" business model, converting waste oils into biodiesel and bio-based materials [3][5] - Fengbei Biological holds EU ISCC certification and has established partnerships with leading agricultural companies and international firms like Shell and BP, positioning itself as a top player in the domestic biodiesel industry [3] Financial Performance - From 2022 to 2024, the company's revenue is projected to increase from 1.709 billion to 1.949 billion yuan, while the net profit attributable to shareholders is expected to decline from 133 million to 124 million yuan, indicating a "revenue growth without profit growth" scenario [5] - The Q3 2025 report shows revenue of 2.251 billion yuan and a net profit of 117 million yuan, reflecting year-on-year growth of 62.32% and 35.32% respectively, but the net profit margin has decreased from 6.97% in the first half of 2024 to 5.21% [5] Market Reaction - After its debut on November 5, the stock experienced a significant drop, with seven out of nine trading days closing lower, plummeting from a peak of 76 yuan to around 47 yuan, highlighting a volatile market response [11][13] - The stock initially surged by 172% on the first day but faced a sharp decline of 14.4% the following day, leading to substantial losses for investors who bought in at higher prices [11][13] Investor Sentiment - Investors expressed frustration over the perceived manipulation of the stock, with claims that the actual controller had already profited through related transactions and cash dividends prior to the IPO, totaling over 65 million yuan [9] - The situation has raised concerns about the role of the underwriting institution, which is seen as prioritizing profit over the quality of the offering, leading to a sentiment of betrayal among retail investors [9][13]

（文章来源：证券日报） 证券日报网讯 12月5日，丰倍生物在互动平台回答投资者提问时表示，公司目前生产经营活动正常，不 触及《上海证券交易所股票上市规则》规定的风险警示情形。二级市场股票价格受到宏观环境、市场环 境、投资者情绪等多个因素的综合影响，敬请投资者注意投资风险。 ...

- The report discusses the IPO performance in November 2025, highlighting that 11 new stocks were listed across the Shanghai, Shenzhen, and Beijing stock exchanges, raising a total of 101.88 billion yuan [2][8] - The average first-day increase for the six new stocks listed on the Shanghai and Shenzhen markets was 209%, with notable variations among individual stocks [2][11] - The report provides a detailed breakdown of the IPO performance by market segment, including the main board, STAR Market, and ChiNext, with specific examples such as Daming Electronics and Hengkun New Materials [11][14] - The report also includes a comprehensive analysis of the monthly IPO subscription returns, with A/B class accounts earning 73.17/71.87 million yuan respectively in November 2025 [14][16] - The report suggests that the "inclusion" strategy remains optimal, recommending active participation in low-priced, small-cap new stocks with high first-day increase potential, as well as large-cap stocks with significant offline allocation [15][17]

- The report introduces a quantitative model for calculating IPO returns based on the formula: **Single account IPO return = min(account size, subscription limit) * winning rate * return rate** **A/B class investors full subscription return = subscription limit * A/B class offline winning rate * return rate** The winning rate considers actual offline IPO results, and the return rate is calculated using the first-day average transaction price relative to the issue price for registered IPOs, or the average transaction price on the opening day for non-registered IPOs[42][43][48] - The model evaluates IPO returns across different market segments (Main Board, ChiNext, STAR Market) and investor classes (A/B). For November 2025, the calculated IPO return rates for a 5-billion-scale account are: **Main Board:** A class: 0.037%, B class: 0.035% **ChiNext:** A class: 0.058%, B class: 0.058% **STAR Market:** A class: 0.046%, B class: 0.045%[43][44][47] - The cumulative IPO return rates for 2025 are: **A class:** 1.716% **B class:** 1.399% These values are based on a 5-billion-scale account participating in all IPOs during the year[49][50][51] - Full subscription returns for November 2025 are calculated as follows: **Main Board:** A class: 19 million yuan, B class: 17.9 million yuan **ChiNext:** A class: 31.3 million yuan, B class: 31.2 million yuan **STAR Market:** A class: 22.8 million yuan, B class: 22.6 million yuan[52][53][55]

Core Insights - The biodiesel sector experienced a decline of 4.59% on November 14, with Hai Xin Energy leading the drop [1] - The Shanghai Composite Index closed at 3990.49, down 0.97%, while the Shenzhen Component Index closed at 13216.03, down 1.93% [1] Stock Performance - International Industrial (000159) closed at 6.85, up 2.24% with a trading volume of 237,400 shares and a transaction value of 163 million [1] - Zhongliang Technology (000930) closed at 6.12, down 0.65% with a trading volume of 153,900 shares and a transaction value of 94.66 million [1] - Pengpeng Environmental (300664) closed at 6.12, down 1.92% with a trading volume of 331,800 shares and a transaction value of 205 million [1] - Excellent New Energy (688196) closed at 61.71, down 4.01% with a trading volume of 25,600 shares and a transaction value of 158 million [1] - Fengbei Biological (603334) closed at 48.30, down 4.03% with a trading volume of 79,100 shares and a transaction value of 38.8 million [1] - Jiaao Environmental (603822) closed at 109.69, down 4.42% with a trading volume of 26,700 shares and a transaction value of 296 million [1] - Shangaohuan Energy (000803) closed at 7.94, down 6.59% with a trading volume of 865,200 shares and a transaction value of 687 million [1] - Hai Xin Energy (300072) closed at 5.56, down 10.03% with a trading volume of 2,447,900 shares and a transaction value of 1.407 billion [1] Capital Flow - The biodiesel sector saw a net outflow of 390 million from main funds, while retail investors contributed a net inflow of 288 million [1] - The detailed capital flow for individual stocks shows varying trends, with International Industrial seeing a net inflow of 3.08 million from main funds, while Hai Xin Energy experienced a net outflow of 150 million [2]

Core Points - Fengbei Bio (603334) experienced a 2.57% increase in stock price with a turnover rate of 36.37% and a trading volume of 589 million yuan, indicating significant market activity [2] - The stock was listed on the Shanghai Stock Exchange due to its high turnover rate, with a net buying amount of 45.77 million yuan from brokerage seats [2] - The top five brokerage seats accounted for a total transaction of 127 million yuan, with a net buying amount of 45.77 million yuan after deducting sales [2] Trading Activity - The largest buying brokerage was Guotai Junan Securities Headquarters, with a purchase amount of 27.46 million yuan, while the largest selling brokerage was Jinyuan Securities Jiangsu Branch, with a selling amount of 10.28 million yuan [2] - The stock saw a net inflow of 71.99 million yuan from main funds, including a net inflow of 34.44 million yuan from large orders [2] - Over the past five days, the net inflow of main funds totaled 71.12 million yuan [2] Financial Performance - For the first three quarters, Fengbei Bio reported a revenue of 2.251 billion yuan, representing a year-on-year growth of 62.32%, and a net profit of 117 million yuan, reflecting a year-on-year increase of 35.32% [2]